Tritert-butyl 11-[5-[[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]-5-oxo-pentanoyl]-1,4,8,11-tetrazacyclotetradecane-1,4,8-tricarboxylate | 208449-64-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: Tritert-butyl 11-[5-[[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]-5-oxo-pentanoyl]-1,4,8,11-tetrazacyclotetradecane-1,4,8-tricarboxylate
• 英文别名: tritert-butyl 11-[5-[[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]-5-oxopentanoyl]-1,4,8,11-tetrazacyclotetradecane-1,4,8-tricarboxylate
• CAS: 208449-64-3
• 化学式: C₄₀H₆₅N₉O₁₂
• 分子量: 864.009
• InChiKey: FZSCJHMFWIZNSP-ILJQZKEFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  61
• 可旋转键数：
  15
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  208
• 氢给体数：
  1
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  Tritert-butyl 11-[5-[[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]-5-oxo-pentanoyl]-1,4,8,11-tetrazacyclotetradecane-1,4,8-tricarboxylate 在 盐酸 作用下， 以 乙醚 为溶剂， 反应 4.0h， 以94%的产率得到3'-azido-3'-deoxy-5'-O-<5-oxo-5-<4,8,11-trihydrochloride-1,4,8,11-tetraazacyclotetradecanyl>pentanoyl>thymidine
  参考文献：
  名称：

  New Bicyclam−AZT Conjugates:  Design, Synthesis, Anti-HIV Evaluation, and Their Interaction with CXCR-4 Coreceptor

  摘要：

  We report the synthesis of mono- and bis-tetraazamacrocycle-AZT conjugates. All new compounds were screened for their ability to inhibit HIV-1 replication in MT4 cell line and were compared to AZT alone. It appears that N-protected covalent prodrugs are equipotent to AZT as inhibitor of HIV replication, while N-deprotected analogues exhibit both higher activity and selectivity against HIV-infected cells. The most active antiviral compounds 27, 28, 34, and 35 were then tested for their binding capability to CXCR-4 receptor. N-Boc analogues 27 and 34 were only weakly effective; in contrast, N-deprotected conjugates 28 and 35 were antagonists to 12G5 mAb binding until 0.05 and 5 mu g/mL, respectively. The stability of compound 28 in human plasma was evaluated, and half-life was found to be approximately 8 h in the described conditions. All these results seem to demonstrate the confidence of our prodrug approach, with analogue 28 emerging as the best candidate as lead compound in HIV-1 polytherapy perspective.

  DOI：

  10.1021/jm980358u
• 作为产物：
  描述：

  1,4,8,11-四氮杂环十四烷 在 4-二甲氨基吡啶 、 碳酸氢钠 作用下， 以 二氯甲烷 为溶剂， 反应 12.5h， 生成 Tritert-butyl 11-[5-[[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]-5-oxo-pentanoyl]-1,4,8,11-tetrazacyclotetradecane-1,4,8-tricarboxylate
  参考文献：
  名称：

  Tri-N-Boc-Tetraazamacrocycle-Nucleoside Conjugates: Synthesis and anti-HIV activities

  摘要：

  As far as linear N-Boc-polyamines conjugates elicited remarkable anti-HIV activity, the synthesis and anti-HIV properties of cyclic N-Boc-polyamines conjugates such as tetraazamacro-cycle-nucleoside were studied. These new conjugates include an ester linkage between the two moieties. They were synthesized using Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate coupling reagent, in the case of N-alkyl polyazamacrocycle derivatives, or through direct condensation of the acyl chloride derivative with nucleoside in the case of N-acyl polyazamacrocycle compounds, None of the new conjugates presented anti-HIV activity greater than that of the corresponding parent nucleosides.

  DOI：

  10.1080/07328319808003466

文献信息

• Tri-N-Boc-Tetraazamacrocycle-Nucleoside Conjugates: Synthesis and anti-HIV activities
  作者：J. Dessolin、P. Vlieghe、M. Bouygues、M. Medou、G. Qúéléver、M. Camplo、J. C. Chermann、J. L. Kraus

  DOI：10.1080/07328319808003466

  日期：1998.5

  As far as linear N-Boc-polyamines conjugates elicited remarkable anti-HIV activity, the synthesis and anti-HIV properties of cyclic N-Boc-polyamines conjugates such as tetraazamacro-cycle-nucleoside were studied. These new conjugates include an ester linkage between the two moieties. They were synthesized using Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate coupling reagent, in the case of N-alkyl polyazamacrocycle derivatives, or through direct condensation of the acyl chloride derivative with nucleoside in the case of N-acyl polyazamacrocycle compounds, None of the new conjugates presented anti-HIV activity greater than that of the corresponding parent nucleosides.
• New Bicyclam−AZT Conjugates:  Design, Synthesis, Anti-HIV Evaluation, and Their Interaction with CXCR-4 Coreceptor
  作者：Jean Dessolin、Pascale Galea、Patrick Vlieghe、Jean-Claude Chermann、Jean-Louis Kraus

  DOI：10.1021/jm980358u

  日期：1999.1.1

  We report the synthesis of mono- and bis-tetraazamacrocycle-AZT conjugates. All new compounds were screened for their ability to inhibit HIV-1 replication in MT4 cell line and were compared to AZT alone. It appears that N-protected covalent prodrugs are equipotent to AZT as inhibitor of HIV replication, while N-deprotected analogues exhibit both higher activity and selectivity against HIV-infected cells. The most active antiviral compounds 27, 28, 34, and 35 were then tested for their binding capability to CXCR-4 receptor. N-Boc analogues 27 and 34 were only weakly effective; in contrast, N-deprotected conjugates 28 and 35 were antagonists to 12G5 mAb binding until 0.05 and 5 mu g/mL, respectively. The stability of compound 28 in human plasma was evaluated, and half-life was found to be approximately 8 h in the described conditions. All these results seem to demonstrate the confidence of our prodrug approach, with analogue 28 emerging as the best candidate as lead compound in HIV-1 polytherapy perspective.